Drug intelligence / Profile preview

AGN-231868

Development stage: Phase 2
Lead developer: AbbVie
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

AGN-231868 is a small molecule chemokine receptor antagonist developed for the treatment of dry eye disease. It was originally developed by Allergan and is now under development by AbbVie. The drug acts by antagonizing chemokine receptors, which are involved in inflammatory pathways implicated in dry eye disease. AGN-231868 has been evaluated in Phase 2 clinical trials as a topical ophthalmic solution to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with dry eye disease[2][3][4][5].

Beyond the preview

Go deeper on AGN-231868.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGN-231868.

Explore the full profile